Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults

Clicks: 356
ID: 269974
2015
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #90 of 183 articles by views in The New England journal of medicine

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 183 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
Among older adults, PCV13 was effective in preventing vaccine-type pneumococcal, bacteremic, and nonbacteremic community-acquired pneumonia and vaccine-type invasive pneumococcal disease but not in preventing community-acquired pneumonia from any cause. (Funded by Pfizer; CAPITA ClinicalTrials.gov n …
Reference Key
mj2015thepolysaccharide Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Bonten MJ;Huijts SM;Bolkenbaas M;Webber C;Patterson S;Gault S;van Werkhoven CH;van Deursen AM;Sanders EA;Verheij TJ;Patton M;McDonough A;Moradoghli-Haftvani A;Smith H;Mellelieu T;Pride MW;Crowther G;Schmoele-Thoma B;Scott DA;Jansen KU;Lobatto R;Oosterman B;Visser N;Caspers E;Smorenburg A;Emini EA;Gruber WC;Grobbee DE;;
Journal The New England journal of medicine
Year 2015
DOI
DOI not found
URL
Keywords

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.